Extended Data Fig. 6: Extracranial tumour growth in Ifng- and Ifngr1-deficient animals.
From: Interferon-γ orchestrates leptomeningeal anti-tumour response
(a) Volumes of intradermal B16 LeptoM flank tumours in C57BL/6 Ifng-proficient and -deficient animals, quantified two weeks after injection. (b) Volumes of mammary fat pad E0771 LeptoM tumours in C57BL/6 Ifng-proficient and -deficient animals, quantified four weeks after injection. (c) Volumes of subcutaneous LLC LeptoM flank tumours in C57BL/6 Ifng-proficient and -deficient animals, quantified three weeks after injection. (d) Volumes of intradermal B16 LeptoM flank tumours in C57BL/6 Ifngr1-proficient and -deficient animals, quantified two weeks after injection. (e) Volumes of mammary fat pad E0771 LeptoM tumours in C57BL/6 Ifngr1-proficient and -deficient animals, quantified four weeks after injection. (f) Volumes of subcutaneous LLC LeptoM flank tumours in C57BL/6 Ifngr1-proficient and -deficient animals, quantified three weeks after injection. (g) Cranial and extracranial in vivo radiance of non-metastatic E0771 Parental cells injected intracardially into C57BL/6 Ifngr1-proficient and -deficient animals two weeks after injection. Notably, one Ifngr1-deficient animal developed histologically confirmed periventricular lesion with cancer cells spread to the contralateral ventricle. (h) Incidence of overt radiographic metastases in cranial (brain), thoracic (lung), and pelvic (femoral bone) regions of C57BL/6 Ifngr1-proficient and -deficient animals from Extended Data Fig. 6g. (i) Cranial and extracranial in vivo radiance of brain-metastatic E0771 BrM2 cells injected intracardially into C57BL/6 Ifngr1-proficient and -deficient animals two weeks after injection. (j) Incidence of overt radiographic metastases in cranial (brain), thoracic (lung), and pelvic (femoral bone) regions of C57BL/6 Ifngr1-proficient and -deficient animals from Extended Data Fig. 6i.
